Биология ва тиббиёт муаммолари 2025, №4.1 (164)

Subject of the article

АРТЕРИАЛ ГИПЕРТЕНЗИЯЛИ БЕМОРЛАРДА СИМПТОМСИЗ ГИПЕРУРЕКЕМИЯ ҲОЛАТИНИ ЎРГАНИШНИНГ ПРОФИЛАКТИК АҲАМИЯТИ (112-117)

Authors

Турғунбоев Саидбурхон Тўлқинжон ўғли, Хамидуллаева Гулноз Абдусатторовн

Institution

Республика ихтисослаштирилган кардиология илмий амалий тиббиёт маркази, Ўзбекистон Республикаси, Тошкент ш.

Abstract

Симптомсиз гиперурекемия (ГУ) артериал гипертензия билан патоген боғлиқликка эга бўлиб, юрак-қон томир, цереброваскуляр ва буйрак касалликлари хавфини оширувчи мустақил хавф омили ҳисобланади. Ушбу мақолада ГУ нинг эпидемиологияси, патогенетик механизмлари ва генетик асослари, хусусан SLC2A9, ABCG2 ҳамда A1CF ген полиморфизмларининг артериал гипертензия (АГ) ривожланишидаги ўрни таҳлил қилинди. Гипертензия юқори хавф гуруҳида ГУ нинг эрта аниқланиши ва хавфни баҳолаш индивидуал даволаш стратегияларини ишлаб чиқишда муҳим аҳамиятга эга. Беморларни назорат қилиш ва даволаш тамойилларини оптималлаштириш юрак-қон томир (ЮҚТ) ҳамда буйрак касалликлари асоратларини камайтириш ва беморларнинг узоқ муддатли прогнозини яхшилашга хизмат қилади.

Key words

симптомсиз гиперурекемия, артериал гипертензия, ген полиморфизми, юрак-қон томир хавфи, буйрак касалликлари.

Literature

1. Benn C.L., Dua P., Gurrell R., et al. Physiology of hyperuricemia and urate-lowering treatments // Frontiers in Medicine (Lausanne). – 2018. – Vol. 5. – P. 160. – DOI: 10.3389/fmed.2018.00160. 2. Bjornstad P., Laffel L., Lynch J., et al. Elevated serum uric acid is associated with greater risk for hypertension and diabetic kidney diseases in obese adolescents with type 2 diabetes: an observational analysis from the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study // Diabetes Care. – 2019. – Vol. 42, No. 6. – P. 1120–1128. – DOI: 10.2337/dc18-2147. 3. Borghi C., Domienik-Karłowicz J., Tykarski A., et al. Expert consensus for the diagnosis and treatment of patients with hyperuricemia and high cardiovascular risk: 2021 update // Cardiology Journal. – 2021. – Vol. 28, No. 1. – P. 1–14. – DOI: 10.5603/CJ.a2021.0001. 4. Chazova I.E., Zhernakova Yu.V., Kislyak O.A., et al. Consensus on patients with hyperuricemia and high cardiovascular risk treatment: 2022 // Systemic Hypertension. – 2022. – Vol. 19, No. 1. – P. 5–22. – DOI: 10.38109/2075-082X-2022-1-5-22. 5. Cicero A.F., Salvi P., D’Addato S., et al.; Brisighella Heart Study group. Association between serum uric acid, hypertension, vascular stiffness and subclinical atherosclerosis: data from the Brisighella Heart Study // Journal of Hypertension. – 2014. – Vol. 32, No. 1. – P. 57–64. – DOI: 10.1097/HJH.0b013e328365b916. 6. Dalbeth N., Choi H.K., Joosten L.A.B., et al. Gout // Nature Reviews Disease Primers. – 2019. – Vol. 5, No. 1. – P. 69. – DOI: 10.1038/s41572-019-0115-y. 7. Drapkina O.M., Mazurov V.I., Martynov A.I., et al. "Focus on hyperuricemia". The resolution of the Expert Council // Cardiovascular Therapy and Prevention. – 2023. – Vol. 22, No. 4. – P. 3564. – DOI: 10.15829/1728-8800-2023-3564. 8. Grayson P.C., Kim S.Y., LaValley M., et al. Hyperuricemia and incident hypertension: a systematic review and meta-analysis // Arthritis Care & Research (Hoboken). – 2011. – Vol. 63, No. 1. – P. 102–110. – DOI: 10.1002/acr.20344. 9. Ichida K., Matsuo H., Takada T., et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia // Nature Communications. – 2012. – Vol. 3. – P. 764. – DOI: 10.1038/ncomms1756. 10. Kobalava Z.D., Konradi A.O., Nedogoda S.V., et al. Arterial hypertension in adults. Clinical guidelines 2020 // Russian Journal of Cardiology. – 2020. – Vol. 25, No. 3. – P. 3786. 11. Koziolova N.A., Chernyavina A.I. Hypertension and asymptomatic hyperuricemia: algorithm of diagnostics and management (literature review) // Arterial’naya Gipertenziya = Arterial Hypertension. – 2022. – Vol. 28, No. 4. – P. 316–327. – DOI: 10.18705/1607419X-2022-28-4-316-327. 12. Leyva F., Anker S., Swan J.W., et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure // European Heart Journal. – 1997. – Vol. 18, No. 5. – P. 858–865. – DOI: 10.1093/oxfordjournals.eurheartj.a015352. 13. Molchanova O.V., Britov A.N., Platonova E.V. Importance of elevated uric acid levels in the development and prevention of chronic non-communicable diseases // Profilakticheskaya Meditsina. – 2020. – Vol. 23, No. 2. – P. 102–108. – DOI: 10.17116/profmed202023021102. 14. Tseng W.C., Chen Y.T., Ou S.M., Shih C.J., Tarng D.C.; Taiwan Geriatric Kidney Disease (TGKD) Research Group. U-shaped association between serum uric acid levels with cardiovascular and all-cause mortality in the elderly: the role of malnourishment // Journal of the American Heart Association. – 2018. – Vol. 7, No. 4. – e007523. – DOI: 10.1161/JAHA.117.007523. 15. Virdis A., Masi S., Casiglia E., et al.; from the Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension. Identification of the uric acid thresholds predicting an increased total and cardiovascular mortality over 20 years // Hypertension. – 2020. – Vol. 75, No. 2. – P. 302. – DOI: 10.1161/HYPERTENSIONAHA.119.13643. 16. Visseren F.L.J., Mach F., Smulders Y.M., et al.; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice // European Heart Journal. – 2021. – Vol. 42, No. 34. – P. 3227–3337. – DOI: 10.1093/eurheartj/ehab484. 17. Williams B., Mancia G., Spiering W., et al.; ESC Scientific Document Group. 2018 ESC/ESH guidelines for the management of arterial hypertension // European Heart Journal. – 2018. – Vol. 39, No. 33. – P. 3021–3104. – DOI: 10.1093/eurheartj/ehy339. 18. Yang Q, Guo CY, Cupples LA, Levy D, Wilson PW, Fox CS. Genomewide search for genes affecting serum uric acid levels: the Framingham Heart study. Metabolism. 2005;54(11):1435-1441.